Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Q3 2026 earnings

Reported November 3, 2026 · Before market open

Revenue$92.1MBeat by $6.6M
EPS-$0.61Beat by $0.10
Revenue estimate$85.6M
EPS estimate-$0.71
“The strength of the U.S. launch through two quarters reinforces both the significant unmet need in acquired HO and our opportunity to transform care for patients living with this serious disease.”
David Meeker

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$92.1M+79.6%
Gross profit$80.0M+74.6%
Operating income-$39.3M+25.4%
Net income-$41.4M+21.8%
EPS (diluted)-$0.61+25.6%

Balance sheet

See full
Cash & equivalents$40.0M-23.2%
Total debt$106.2M-6.1%
Total equity$88.0M-40.9%
Total assets$443.1M-12.6%

Cash flow

See full
Operating cash flow-$3.1M+88.5%

Valuation & ratios

Valuation

as of 11/03/26
See full
Market cap$6.43B-14.8%
Enterprise value$6.5B-14.7%
P/S22.9×-20.4×

Profitability

See full
Gross margin88.2%-1.2pp
Operating margin-66.7%-18.2pp
Net margin-69%-18.8pp

Returns & leverage

See full
Return on equity-163.7%-39.6pp
Debt / equity1.2×+0.4×
Current ratio2.8×-2.0×

Segments

By segment

See full
Single reportable segment$92.1M+79.6%

By product

See full
License revenue-—

FAQ

When did Rhythm Pharmaceuticals, Inc. report Q3 2026 earnings?
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q3 2026 earnings on November 3, 2026 before market open.
What were Rhythm Pharmaceuticals, Inc.'s Q3 2026 revenue and EPS?
Rhythm Pharmaceuticals, Inc. reported revenue of $92.1M and eps of $-0.61 for Q3 2026.
Did Rhythm Pharmaceuticals, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $85.6M by $6.6M. EPS beat the consensus estimate of $-0.71 by $0.10.
How did Rhythm Pharmaceuticals, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 79.6% from $51.3M a year earlier and eps grew 25.6% from $-0.82.
Where can I find Rhythm Pharmaceuticals, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-069106) and the 10-Q periodic report (0001628280-26-069485) directly on SEC EDGAR. The filing index links above go to sec.gov.